Despite high rates of comorbid insomnia among children and adolescents with Autism Spectrum Disorder (ASD), and its negative impact on child development, health and quality of life, there is limited awareness among clinicians of screening for, and treatment of, insomnia in this population. Prolonged-Release Melatonin (PedPRM, available commercially as Slenyto®) is the first authorized drug for the management of insomnia in children and adolescents with ASD or Smith Magenis Syndrome (SMS) but there is little evidence on how this new medicinal product performs in real life treatment

Direct Link:

Journal: Ann Clin Case Rep. 2022; 7.;2176

Keywords: ASD, autism spectrum disorder, children, Insomnia, melatonin, paediatric prolonged release sleep, Sleep,

Applications: Sleep,

CamNtech Reference: M22041

Back to Search Results

UK & International customers

CamNtech Ltd.
Manor Farm
PE28 9JD, UK

US customers

CamNtech Inc.
630 Boerne Stage Airfield,
Texas 78006,


© 2022 CamNtech Ltd and CamNtech Inc

Company information

Registered in England No. 2221302
VAT No: GB486 3019 34

Privacy Policy